Monthly Archives: September 2019

Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

20190930 PR TG4001 ESMO EN

By nh|2019-11-05T09:54:59+01:00September 30th, 2019|Press release, TG4001, TG4001|Comments Off

Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers

Christophe Le Tourneau et al. ESMO 2019 Download the poster [...]

By Lucie Larguier|2020-07-22T14:04:14+02:00September 30th, 2019|Publication, TG4001, TG4001|Comments Off

Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results

20190918-Transgene-H1-2019-RESULTS-EN

By axc|2019-10-01T10:39:54+02:00September 18th, 2019|Press release|Comments Off

2019 Half-Year Results and Business Update

https://channel.royalcast.com/webcast/transgene/20190918_1/

By axc|2019-09-18T10:47:26+02:00September 18th, 2019|Webcast|Comments Off

Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050

20190916 PR ANSM TG4050 EN

By nh|2020-04-23T15:54:37+02:00September 16th, 2019|Myvac, Press release, TG4050|Comments Off